NEWSFLASH! The Oesophageal Doppler team delivered a workshop as part of the recent NHS Midlands and East Innovation EXPO. Click here for further details.
Implementing three technologies across the East Midlands
1.Introduction
The national Quality, Innovation ,Productivity and Prevention programme (QIPP) aims to improve the quality of healthcare through innovation and better prevention, thereby enabling health monies to be used more effectively.
A key part of enabling this is the Innovative Technology Adoption Procurement Programme (iTAPP) which is part of the ambitious National Innovation Procurement Plan. iTAPP aims to bring coherence and clarity to technology adoption by focussing on the rapid adoption and diffusion of selected technology-driven innovations that have the most potential for helping the NHS to meet the quality and productivity challenge.
The iTAPP programme is led by the Department of Health’s (DH) Innovation Procurement and Commercial division in collaboration with the National Technology Adoption Centre (NTAC) and the medical technology industry.
As part of this innovative programme, industry suppliers of health technologies and products were invited to recommend innovations that could increase quality and reduce cost for the NHS.
2. Top 3 innovation interventions for adoption
It is the intention to support the adoption of three technologies from the iTAPP list across the East Midlands by the end of June 2011. The first intervention identified for implementation is the oesophageal Doppler.
NHS Trust Chief Executives, the regional Clinical Cabinet and the Planned Care Board agreed to support its use as part of the implementation of Enhanced Recovery After Surgery Programme (ERAS) in the East Midlands.
Consequently, Chief Executives, innovation leads, surgery leads, anaesthetists, procurement leads and Trust ERAS Leads are being engaged in a series of road shows to cascade learning and data to support the use of this product in specific types of surgery.
3.Partnership support for implementation
The DH team have commissioned the NHS Technology Adoption Centre (NTAC) to support SHAs in this implementation process and transfer learning to the NHS on how to implement innovative technologies.
NTAC was formed to realise the opportunities of bringing together the regional focus on innovation and commercial support at SHA level, with the aim of building relationships with industry to support the delivery of greater quality and productivity in the NHS.
NTAC’s work with SHAs involves supporting innovation and commercial support unit leads in SHAs to collaborate with partners across their health economy with the aim of identifying, understanding and dismantling systemic and commercial barriers to adoption.
4. Oesophageal Doppler adoption programme
The Oesophageal Doppler is used within major surgical procedures such as cancer, transplantation, orthopaedics, colorectal, gynaecology and urology.
Dr Sonia Swart, Chair of the Planned Care Board in the East Midland and Medical Director of Northamptonshire General Hospital said: “We are really pleased that through the East Midlands Planned Care Clinical Advisory Group, we have secured the commitment and support to roll-out this innovative tool across the region.”
Dr Swart added “together with Dr Stuart Gold, Consultant Anaesthetist at Derby Hospitals NHS Foundation Trust, who has piloted the use of the Doppler in colo-rectal surgery, we are generating further interest and support amongst the clinicians in the East Midlands. This will ensure an increase in the quality of care for patients, decrease the potential for unnecessary harm and a reduction in lengths of stay in hospitals.”
Key benefits of the technology
-
Minimally invasive: The probe is inserted into the oesophagus when the patient is asleep. Minimal training is required for the insertion and removal of the Doppler, and for use of the monitor.
-
Reduced risk: Fewer complications compared to other invasive monitoring techniques.
-
Improved patient outcomes: Doppler-guided fluid management ensures adequate blood perfusion to major organs and reduces post-operative complications. Use of the oesophageal doppler reduces the need for more invasive monitoring devices, such as central venous catheters.
-
Reduced hospital stay: Better organ perfusion intra-operatively allows patients to return to normal functioning more quickly, which leads to an overall reduction in the length of patient stay.
-
Benefits to patients and the NHS: Fewer complications will enhance patient experience. A reduction in lengths of stay for patients as a result, will enhance efficiency and improve patient care pathways.
For more information on the East Midlands approach to Enhanced Recovery, click here
Dr Stuart Gold, Consultant Anaesthetist at Derby Hospitals NHS Foundation Trust has recorded here the learning from the Trust’s involvement in the National Technology Adoption Centre (NTAC) adoption project to roll out the Doppler as part of Enhanced Recovery After Surgery.
Click HERE to listen to the podcast.
For link to feature shown on BBC East Midlands Click HERE
News! -
NICE have released guidance which supports the use of the CardioQ-ODM monitor in surgery – see below
1.1 The case for adopting the CardioQ-ODM in the NHS, when used as described in 1.2, is supported by the evidence. There is a reduction in post-operative complications, use of central venous catheters and in-hospital stay (with no increase in the rate of re-admission or repeat surgery) compared with conventional clinical assessment with or without invasive cardiovascular monitoring. The cost saving per patient, when the CardioQ-ODM is used instead of a central venous catheter in the peri-operative period, is about £1100 based on a 7.5-day hospital stay.
1.2 The CardioQ-ODM should be considered for use in patients undergoing major or high-risk surgery or other surgical patients in whom a clinician would consider using invasive cardiovascular monitoring."
See this news article: http://www.bbc.co.uk/news/health-12899316
See here for the guidance
See below for downloads
